Chikungunya Virus Infection Clinical Trial
Official title:
A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above
This was a prospective, randomized, double-blinded, multicenter, pivotal clinical study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control was administered as single immunization on Day 1. Overall, 4.128 male and female subjects aged 18 years and above were randomized into the study.
This was a prospective, double-blinded, multicenter, randomized, pivotal Phase 3 study and 4.128 participants aged 18 years or above were randomized in a 3:1 ratio to the live-attenuated CHIKV vaccine candidate (VLA1553) or placebo. The final dose of lyophilized VLA1553 or placebo was administered as a single intramuscular immunization. Subjects in this study were stratified into two age strata of 18 to 64 years and 65 years of age or above. The primary objective of the study was to evaluate the immunogenicity and safety of the final dose of VLA1553 28 days following the single immunization. Immunogenicity evaluations in the immunogenicity subset included the proportion of subjects with seroprotective neutralizing CHIKV antibody titers above a surrogate threshold indicative of protection. The surrogate of protection reasonably likely to predict clinical benefit has been established in non-human primate passive transfer studies using human sera from the Phase 1 study and was supported by sero-epidemiological studies. Safety data collection and immunogenicity were assessed until Month 6. The first enrolled and randomized 501 subjects comprised the immunogenicity subset. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02230163 -
Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins
|
Phase 1/Phase 2 | |
| Terminated |
NCT04455919 -
Yoga for Chronic Chikungunya
|
N/A | |
| Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
| Active, not recruiting |
NCT04441905 -
Phase 1 Study of SAR440894 vs Placebo
|
Phase 1 | |
| Completed |
NCT02562482 -
Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
|
Phase 2 | |
| Completed |
NCT03028441 -
Phase I Trial of Measles Vectored Chikungungya Vaccine
|
Phase 1 | |
| Completed |
NCT03807843 -
Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
|
Phase 2 | |
| Completed |
NCT04909411 -
Consequences of a Maternal-fetal Chikungunya Virus Infection
|
N/A | |
| Completed |
NCT04786444 -
Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults
|
Phase 3 | |
| Completed |
NCT02553369 -
Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection
|
N/A | |
| Recruiting |
NCT06106581 -
A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years
|
Phase 2 | |
| Recruiting |
NCT06007183 -
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
|
Phase 3 | |
| Completed |
NCT03635086 -
Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)
|
Phase 2 | |
| Completed |
NCT02861586 -
Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine
|
Phase 2 | |
| Active, not recruiting |
NCT04838444 -
Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)
|
Phase 3 | |
| Completed |
NCT03483961 -
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
|
Phase 2 | |
| Recruiting |
NCT06028841 -
A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)
|
Phase 3 |